Pharming and Transmedic announce distribution agreement for RUCONEST
(Thomson Reuters ONE) -
Leiden, The Netherlands, February 14, 2012. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has
entered into an agreement with Transmedic Pte Ltd. (Transmedic), a privately
owned Singapore based specialty healthcare company, for the commercialization of
RUCONEST(®) (recombinant human C1 inhibitor) for the treatment of acute attacks
of Hereditary Angioedema (HAE) in parts of South- East Asia. The South- East
Asian territories covered under this agreement include Brunei, Indonesia,
Malaysia, Philippines, Singapore, and Thailand.
Under the agreement, Transmedic will drive the respective regulatory approvals
and purchase its commercial supplies of RUCONEST from Pharming at a fixed
transfer price.
Sijmen de Vries, CEO of Pharming, commented: "We are pleased to have taken
another step towards making RUCONEST, an innovative, highly effective and safe
replacement therapy, available to HAE patients globally. In Transmedic we have
found an experienced commercialization partner dedicated to bringing innovative
specialty medicines to this region. Transmedic's proven ability to cater for
specialty medical care in hospitals provides an excellent platform from which
RUCONEST can be made available to doctors and HAE patients in these countries."
Teo Kee Meng, Managing Director of Transmedic, said: "Being able to add RUCONEST
to our portfolio is another example of our continuous drive to bring the most
innovative products in specialty medicine, to fulfill the unmet medical needs
for patients and doctors, into our rapidly developing region; we are very
excited about the potential of RUCONEST in HAE and the future indications that
RUCONEST may be developed for."
About RUCONEST (RHUCIN in non-European territories) and Hereditary Angioedema
RUCONEST(®) (INN conestat alfa) is a recombinant version of the human protein C1
inhibitor (C1INH). RUCONEST is produced through Pharming's proprietary
technology in milk of transgenic rabbits and in Europe is approved under the
name RUCONEST( )for treatment of acute angioedema attacks in patients with HAE.
RHUCIN(®) is an investigational drug in the U.S. and has been granted orphan
drug designation for the treatment of acute attacks of HAE, a genetic disorder
in which the patient is deficient in or lacks a functional plasma protein C1
inhibitor, resulting in unpredictable and debilitating episodes of intense
swelling of the extremities, face, trunk, genitals, abdomen and upper airway.
The frequency and severity of HAE attacks vary and are most serious when they
involve laryngeal edema, which can close the upper airway and cause death by
asphyxiation. According to the U.S. Hereditary Angioedema Association,
epidemiological estimates for HAE range from one in 10,000 to one in 50,000
individuals.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant
human C1 inhibitor approved for the treatment of angioedema attacks in patients
with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is
distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN(®) is
partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is
undergoing Phase III clinical development. The product is also being evaluated
for follow-on indications in the areas of transplantation and reperfusion
injury. The advanced technologies of the Company include innovative and
validated platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. Recently a new
project, using the validated transgenic rabbit platform, aimed at the
development of recombinant Factor VIII for the treatment of Haemophilia A was
initiated was initiated by partner, Renova Life, Inc. Additional information is
available on the Pharming website, www.pharming.com.
About Transmedic Pte Ltd
Transmedic Pte Ltd was established in 1980 and has close to 30 years of valuable
industry experience, in-depth knowledge & skills in the field of cutting-edge
medical technologies and healthcare treatment.
Today, Transmedic is a leading medical specialty partner of world-class
healthcare institutions and professionals in Southeast Asia. With its
headquarters in Singapore, branch offices in Malaysia, Thailand, Indonesia, Hong
Kong & Philippines, and sub-distributors in Cambodia, Vietnam, Brunei &
Pakistan, Transmedic has a comprehensive regional network for the most strategic
approach to effectively distributing specialty medical devices and specialty
medicine. For more information, please visit http://www.transmedic.com.sg.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact
Sijmen de Vries, CEO: T: +31 (0) 71 524 7400
Karl Keegan, CFO: T: +31 (0) 71 524 7400
FTI Consulting
Julia Phillips/ John Dineen, T: +44 (0)207 269 7193
# # #
Press release (PDF):
http://hugin.info/132866/R/1585287/496278.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1585287]
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 114094
Anzahl Zeichen: 6517
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming and Transmedic announce distribution agreement for RUCONEST"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
